动脉高血压与 COVID-19 严重程度和死亡率的关系。
Arterial hypertension and the risk of severity and mortality of COVID-19.
机构信息
Faculty of Medical Sciences, National University of La Plata, Buenos Aires, Argentina, and Argentinian Society of Arterial Hypertension (SAHA)
Faculty of Medical Sciences, National University of La Plata, Buenos Aires, Argentina, and Argentinian Society of Arterial Hypertension (SAHA).
出版信息
Eur Respir J. 2020 Jun 11;55(6). doi: 10.1183/13993003.01148-2020. Print 2020 Jun.
Abstract
摘要
[链接]
相似文献
1
Arterial hypertension and the risk of severity and mortality of COVID-19.动脉高血压与 COVID-19 严重程度和死亡率的关系。
Eur Respir J. 2020 Jun 11;55(6). doi: 10.1183/13993003.01148-2020. Print 2020 Jun.
2
SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: a systematic review.SARS-CoV-2 感染合并糖尿病和高血压的患者：一项系统综述。
Rev Cardiovasc Med. 2020 Sep 30;21(3):385-397. doi: 10.31083/j.rcm.2020.03.78.
3
The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates.高血压与新冠病毒肺炎患者严重程度及死亡率的关联：基于校正效应估计值的证据
J Infect. 2020 Sep;81(3):e44-e47. doi: 10.1016/j.jinf.2020.06.060. Epub 2020 Jun 25.
4
[Diabetes and hypertension as factors associated with Covid-19 lethality in Sonora, Mexico, 2020].[2020年，糖尿病和高血压作为墨西哥索诺拉州与新冠病毒致死率相关的因素]
Salud Publica Mex. 2020 Sep-Oct;62(5):456-457. doi: 10.21149/11546.
5
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
6
Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China.中国武汉严重肺炎患者的临床特征。
Respiration. 2020;99(8):649-657. doi: 10.1159/000507940. Epub 2020 Aug 25.
7
Cardiovascular comorbidity and its impact on patients with COVID-19.心血管合并症及其对 COVID-19 患者的影响。
Eur Respir J. 2020 Jun 11;55(6). doi: 10.1183/13993003.01227-2020. Print 2020 Jun.
8
In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.在患有高血压的COVID-19患者中，住院期间使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂与较低的死亡率和危重症风险相关。
J Infect. 2020 Nov;81(5):816-846. doi: 10.1016/j.jinf.2020.08.014. Epub 2020 Aug 12.
9
Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients.丹麦新冠肺炎患者的Charlson合并症指数评分与严重后果及死亡风险
J Gen Intern Med. 2020 Sep;35(9):2801-2803. doi: 10.1007/s11606-020-05991-z. Epub 2020 Jun 24.
10
The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.高血压、血管紧张素转换酶2（ACE-2）与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）之间的相互作用：新出现的数据成为2019冠状病毒病（COVID-19）“迷宫”中的“阿里阿德涅之线” 。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):31-33. doi: 10.1016/j.hjc.2020.05.003. Epub 2020 May 22.
引用本文的文献
1
Efficient and scalable construction of clinical variable networks for complex diseases with RAMEN.利用RAMEN高效且可扩展地构建复杂疾病的临床变量网络
Cell Rep Methods. 2025 Apr 21;5(4):101022. doi: 10.1016/j.crmeth.2025.101022. Epub 2025 Apr 10.
2
Predictive significance of hypertension in the incidence of complications in critically ill patients with COVID‑19: A retrospective cohort study.高血压对新型冠状病毒肺炎危重症患者并发症发生率的预测意义：一项回顾性队列研究
Med Int (Lond). 2024 Oct 9;4(6):74. doi: 10.3892/mi.2024.198. eCollection 2024 Nov-Dec.
3
STUDY HYPOTHESIS: AGE, GENDER, PRESENCE OF DIABETES MELLITUS OR HYPERTENSION, AND ANTI-HYPERTENSIVE DRUGS ARE INDEPENDENT RISK FACTORS FOR COVID-19 MORTALITY.研究假设：年龄、性别、糖尿病或高血压的存在以及抗高血压药物是 COVID-19 死亡率的独立危险因素。
Acta Clin Croat. 2023 Nov;62(3):447-456. doi: 10.20471/acc.2023.62.03.6.
4
Knowledge, attitudes, and practices of chronic disease patients in Bojanala towards COVID-19.博若莱地区慢性病患者对 COVID-19 的认知、态度和实践。
S Afr Fam Pract (2004). 2023 Oct 30;65(1):e1-e8. doi: 10.4102/safp.v65i1.5763.
5
Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations.药物再利用治疗 COVID-19 及其心血管表现。
Circ Res. 2023 May 12;132(10):1374-1386. doi: 10.1161/CIRCRESAHA.122.321879. Epub 2023 May 11.
6
Initial mean arterial blood pressure (MABP) measurement is a risk factor for mortality in hypertensive COVID-19 positive hospitalized patients.初始平均动脉血压（MABP）测量是 COVID-19 阳性住院高血压患者死亡的一个危险因素。
PLoS One. 2023 Mar 30;18(3):e0283331. doi: 10.1371/journal.pone.0283331. eCollection 2023.
7
Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients.评估尿半胱氨酰白三烯作为 COVID-19 患者严重程度的生物标志物和潜在治疗靶点。
Inflamm Res. 2023 Mar;72(3):475-491. doi: 10.1007/s00011-022-01682-z. Epub 2023 Jan 8.
8
Hypertension and mortality in SARS-COV-2 infection: A meta-analysis of observational studies after 2 years of pandemic.高血压与 SARS-CoV-2 感染患者的死亡率：大流行 2 年后的观察性研究的荟萃分析。
Eur J Intern Med. 2023 Feb;108:28-36. doi: 10.1016/j.ejim.2022.11.018. Epub 2022 Nov 17.
9
A Review of Routine Laboratory Biomarkers for the Detection of Severe COVID-19 Disease.用于检测重症 COVID-19 疾病的常规实验室生物标志物综述
Int J Anal Chem. 2022 Oct 11;2022:9006487. doi: 10.1155/2022/9006487. eCollection 2022.
10
Identifying shared genetic loci between coronavirus disease 2019 and cardiovascular diseases based on cross-trait meta-analysis.基于跨性状荟萃分析确定2019冠状病毒病与心血管疾病之间的共享基因位点。
Front Microbiol. 2022 Sep 15;13:993933. doi: 10.3389/fmicb.2022.993933. eCollection 2022.
本文引用的文献
1
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.中国 COVID-19 患者 1590 例的合并症及其影响：一项全国性分析。
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.00547-2020. Print 2020 May.
2
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究：中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
3
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.合并症的患病率及其对 SARS-CoV-2 感染患者的影响：系统评价和荟萃分析。
Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
[Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19].新型冠状病毒肺炎患者心肌损伤分析及合并心血管疾病与新型冠状病毒肺炎严重程度的相关性
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):567-571. doi: 10.3760/cma.j.cn112148-20200225-00123.
6
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
7
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
8
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
Zotero 插件